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ABSTRACT  OF  THE  DISSERTATION
Objective : An audit of the use and outcomes of Radioactive Iodine (RAI) therapy
in the definitive management of thyrotoxicosis at Inkosi Albert Luthuli Central
Hospital (IALCH), KwaZulu-Natal, South Africa.
Methods : The clinical records of all new patients with thyrotoxicosis, referred in a
4 year period between 01/01/2003 and 31/12/2006, were analysed. Response to
RAI was monitored using biochemical parameters (namely, Thyroid Stimulating
Hormone and Free T4 levels). Rates of euthyroidism (cure), hypothyroidism and
hyperthyroidism (treatment failure) were correlated to dose of RAI. Patients were
followed-up for at least 2 years or until the onset of hypothyroidism. The follow-up
period was until 31/12/2007.
Results : One hundred and fourteen patients (37.7%), of a cohort of 302 new
thyrotoxic patients treated with RAI, met the inclusion criteria. Ninety-six patients
(84.2%) had Graves Disease (GD) whilst 18 had Toxic Nodular Disease (TND).
At 2 year follow-up, 91 patients (79.8%) were hypothyroid, 10 (8.8%) were
euthyroid and 13 (11.4%) were hyperthyroid. The average dose of RAI to achieve
euthyroidism was 10mCi and hypothyroidism, 9.7mCi. The average time to achieve
euthyroidism was 5.9 months and 10.1 months to become hypothyroid. Thirty-one
patients (27.2%) remained persistently hyperthyroid after one dose of RAI.
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Patients with GD (88.5%) were more likely to become hypothyroid (p < 0.001)
whilst 38.9% of TND patients remained hyperthyroid (p = .001). Baseline TFT values
were significant in terms of outcomes correlated with the prescribed RAI dose i.e
Low Dose (<8mCi) vs. Intermediate Dose (8-9mCi) vs. High Dose (>9mCi)(TSH p =
0.05; FT4 p = 0.003; FT3 p = 0.001).
Conclusion : The majority of patients became hypothyroid over time, in keeping
with reported data. In the public health sector, where early access to RAI (in terms
of waiting times for appointments for RAI) and follow-up are major problems, early
cure is essential to minimize the morbidity of thyrotoxicosis and this may be
achieved with an initial high dose of RAI.
CHAPTER 1 : INTRODUCTION
Radioactive Iodine (RAI) has been used in the management of thyroid disorders for
over 70 years.1 In an age of rapid emergence of radiopharmaceuticals, RAI
represents the prototype therapy in radiation medicine, with its list of clinical
indications continually expanding.2
In the South African public healthcare system where patients with thyrotoxicosis
commonly present late and experience delays in diagnosis and referral, the role of
RAI in the early management of thyrotoxicosis is crucial.3 Rapid, effective
intervention is often required to render patients euthyroid. Due to a lack of Nuclear
Medicine physicians in KwaZulu-Natal, RAI is prescribed by Clinical Oncologists
working in the Department of Radiotherapy and Oncology at Inkosi Albert Luthuli
Central Hospital (IALCH) and Addington Hospital. Long waiting lists for first visit
appointments at the Oncology clinic result in thyrotoxic patients being commenced
on Anti-Thyroid Drugs (ATDs) to control moderate-to-severe thyrotoxicosis before
definitive therapy with RAI.
Thyroidectomy and ATDs remain viable options for the management of selected
patients with thyrotoxicosis, but these modalities have been superseded by RAI in
the last two decades, particularly in the United States of America.4
Hypothyroidism is the commonest side-effect of RAI therapy.1,5,6,7,8,9 This usual
consequence of RAI treatment is considered by endocrinologists, nuclear medicine
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physicians and radiation oncologists to be an acceptable end-point of RAI
therapy.8,10,11 The development of hypothyroidism is easily managed with thyroid
hormone supplementation and the available data suggests that this therapy confers
a benefit in terms of reducing long-term morbidity and mortality associated with
thyrotoxicosis.12,13
RAI therapy is also reported to be associated with a modest increase in risk of
secondary malignancy. Large epidemiological studies of RAI in the management of
thyrotoxicosis have identified a cancer-associated standardized mortality ratio (SMR)
of 1.02, that is not considered clinically significant (95% CI 0.98-1.07) for doses of
RAI ranging between 7-10mCi14,15,16,17; the clinical benefit of RAI outweighs the risk
of carcinogenecity.1
The need for life-long monitoring of thyroid function and follow-up to evaluate for
the development of secondary malignancy is well-recognised.1 Follow-up at primary
care level is lacking and, unlike in the developed world, the responsibility of follow-
up is borne by regional and tertiary facilities.
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CHAPTER 2 : THYROTOXICOSIS
Indications for Radioactive Iodine
Radioactive Iodine has been used in a number of benign thyroid diseases, often with
different dose regimens and with variable treatment intents.9,13,18,19,20 Amongst the
common indications for the use of RAI are : Graves’ disease (GD), toxic multinodular
goitre (MNG), toxic adenoma (TA) and non-toxic goitre.
Graves’ Disease
Graves’ disease (GD) is an autoimmune disease characterized by thyroid hyper-
function that is initiated by stimulatory auto-antibodies to the thyrotropin (TSH)
receptor protein which is located on the thyrocyte cell membrane. The thyroid
stimulating antibodies bond to the TSH receptor, activating adenylate cyclase,
resulting in increased thyroid hormone production, increase in thyroid gland size and
increased vascularity.21
GD is a condition that is typically characterized by episodes of remission and relapse.
GD is more common in young adults and in females and accounts for between 60-
80% of all cases of thyrotoxicosis. It may be familial and may also be associated
with other autoimmune diseases. Up to 50% of patients with GD may also have an
infiltrative ophthalmopathy.21
The diagnosis of GD is made by a combination of clinical, biochemical and
scintigraphic findings. Clinically, patients present with a diffuse goiter with or without
a bruit, characteristic eye signs (including proptosis and ophthalmoplegia), signs and
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symptoms of hyperthyroidism or a concomitant autoimmune disease. Biochemically,
serum TSH is low and serum FT4 and FT3 are elevated. Thyroid antibodies are
usually elevated. Radionuclide uptake scans show a diffuse, uniformly increased
uptake of the radioisotope.1
Treatment options in GD include : antithyroid drugs, thyroidectomy and RAI – all of
which have their own benefits and risks.4,21,22 The use of steroids in GD is only
advocated in the setting of severe ophthalmopathy.7
Toxic Multinodular Goitre
Toxic multinodular goitre (MNG) is characterized by mixed population of hyper-
functioning and hypo-functioning nodules embedded in normal thyroid tissue. It is
more common in adults over the age of 50 and in females. The proposed aetiology
includes goitrogens, hereditary factors, environmental factors and hormonal factors.
Toxic MNG is up to ten times more common in iodine-deficient areas.  The nodules
in a toxic MNG are said to be autonomous i.e. independent of control exerted by
TSH. Advances in molecular biology have suggested that nodular proliferation is
caused by over-expression of the RAS proto-oncogene, resulting in TSH receptor
activation and up-regulation of cyclic adenosine monophosphate (cAMP)
signaling.23,24,25
The diagnosis of toxic MNG is made on clinical, biochemical and radiological studies.
Patients often present with a nodular goitre and signs and symptoms of
hyperthyroidism. These are usually older patients with long-standing disease and
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they typically also have co-morbid thyrocardiac manifestations. Biochemically, TSH is
suppressed and FT4 and FT3 are elevated. Thyroid antibodies are usually negative.
Ultrasound scan of the thyroid demonstrates a nodular thyroid whilst radionuclide
thyroid scan is characterized by heterogenous uptake with foci of increased irregular
uptake corresponding to the autonomous nodules.1,23
Toxic Adenoma
Toxic adenoma (TA) refers to a solitary autonomous hyper-functioning nodule in the
thyroid parenchyma. Thyroid tissue is composed of a small fraction of cells with an
inherent ability to proliferate in the absence of a recognizable stimulus. This
replicative potential results in local hyperplasia and eventually, the formation of an
adenomatous nodule. Less than 25% of all adenomas will secrete thyroid hormones.
Inactive nodules have a finite life-span and usually undergo degeneration and
apoptosis. Toxic adenoma is a condition with a slow evolution, but tends to occur in
slightly younger patients than toxic MNG.1,25,26
Patients usually present with symptoms of thyrotoxicosis, with a palpable nodule in
the thyroid gland. The thyroid function test reflects this toxicosis and thyroid
scintigraphy is very accurate in delineating a nodule which intensely concentrates
the radionuclide.1,23
Non-Toxic Goitre
Non-toxic goitre refers to thyroid enlargement in the absence of hyperthyroidism.
This may arise sporadically or may occur in endemic areas of iodine deficiency.
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Incidence increases with age and it is more common in females. These goitres
increase in size progressively, but at a variable rate. They eventually come to
medical attention due to cosmetic or obstructive symptoms. Whilst surgery remains
the mainstay in the treatment of this condition, RAI has been used to effect a
reduction in the size of the thyroid gland, with favourable results.25
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CHAPTER 3 : RADIOACTIVE IODINE
Radioactive Iodine : A Historical Perspective
The discovery of RAI as a diagnostic and therapeutic tool in the management of
benign and malignant thyroid disorders is widely considered to have heralded the
birth of Nuclear Medicine as a speciality. This was preceded by pioneering work in
the fields of thyroid physiology and radiochemistry. The integration of these two
fields in the 1940s was the ultimate precursor to RAI which is used worldwide in the
clinical setting today.27,28
In 1895, Baumann described the presence of iodine in the thyroid gland.
Subsequently, Marine discovered that the thyroid cleared iodine from the blood.
Kendall isolated a crystal form of iodine, now known as thyroxine.25
These physiological discoveries were paralleled in the field of radiochemistry, by the
work of Henri Becquerel who, in 1896 in collaboration with Marie Curie discovered
radioactivity. During the same generation, Ernest Rutherford proposed the concepts
of half-life and the decay constant. Alpha (), beta () and gamma () radiation
were characterised. The Curies experimented extensively with radioactivity as a
medical adjunct. In 1913, Abbe used Radium to treat hyperthyroidism.25
Many new radioisotopes were discovered during this period. Additionally, scientists
started to manufacture artificial radioisotopes. By the 1930s, research into the
applications of radionuclides was relentless, both in the clinical and laboratory
8
setting. As with earlier work in the field of radioactivity, much of the research in
radionuclide use was centred around the management of malignancies.27
Radioactive iodine was discovered prior to the Second World War. Early experiments
involved laboratory animal thyroid physiology. The war however, resulted in a slow-
down in this research, as the attentions of the radio-physicists were channelled into
the production of the Atomic Bomb. The subsequent carnage in Hiroshima and
Nagasaki has ultimately proved to be both beneficial and detrimental to the
development and use of radionuclides in the clinical setting. On the one hand,
nuclear radiation became shackled with negative connotations whilst on the other,
survivors of the bombings provided vital information on the effects of radiation in
long-term follow-up studies.25
In 1942, radioactive iodine was first reported to be used in the treatment of thyroid
cancer. Patients who were faced with a dismal prognosis were being offered the
chance of a cure. The dramatic results obtained resulted in a fast-tracking of
radioisotopes into clinical use via the Atomic Energy Act of 1946. In 1951, the Food
and Drug Administration (FDA) in the United States of America approved radioactive
iodine for the treatment of benign thyroid diseases.29
Radioactive iodine has been used to elucidate the finer details of thyroid physiology,
from the uptake mechanism of iodine, to the synthesis of thyroid hormone and
serum transport of these hormones.27
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The -emitting properties of radioactive iodine were harnessed by Anger and
colleagues who developed the gamma camera that facilitated imaging of the thyroid,
thereby providing valuable information on a wide range of thyroid disorders. This
was later superseded by the discovery and use of Technetium-99 (99mTc).28
Indeed, 131I is considered to be the fore-runner of numerous radiopharmaceuticals,
including 18-Fluorodeoxyglucose (18FDG) which is widely used in Positron Emission
Tomography (PET) scanning, 90-Yttrium labelled ibritumomab tiuxetan which is used
in follicular B-cell lymphoma and 89-Strontium, used in the palliation of bone
metastases. 131I has found other uses in clinical oncology, namely in the
management of neuroendocrine tumours like phaeochromocytomas, using 131I mIBG
and 131I-tositumomab which is used in the treatment of relapsed refractory follicular
B-cell lymphoma.27
The Radiobiology of Radioactive Iodine
The biological basis of RAI therapy lies fundamentally in the ability of the thyroid
gland to concentrate iodine. Negligible amounts of iodine are taken up in the salivary
glands, stomach and bladder.30
Radioactivity is defined as the number of nuclear disintegrations per second. The
unit of radioactivity used at our centre, both in the departments of Nuclear Medicine
and Radiation Oncology, is the milliCurie (mCi) which is equal to 3.7 x 107
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disintegrations per second. The other unit of radioactivity  used at other centres is
the Mega Becquerel (MBq) which equates to 106 disintegrations per second. By
mathematical deduction, 1mCi = 37MBq.28
The “Absorbed Dose” refers to the amount of energy transferred by ionizing
radiation to a given mass of tissue. It is expressed in Joules per kilogram (J/kg) and
the SI unit is the gray (Gy).28
The “Effective Dose” seeks to standardize or weight the radiation exposure since
different types of tissue react differently to different types of radiation. The SI unit
for effective dose is the milliSievert (mSv) and this has important implications in the
field of Radiation Protection.28
Radioactive Iodine (131I) decays with a physical half-life of 8.1 days.  The biological
half-life of 131I is highly variable and is determined by the clearance of 131I from the
thyroid. The mean effective half-life is a combination of the biological and physical
half-lives and approximates 6 days. Approximately 80% of 131I is cleared renally.
The decay of 131I is by Beta () particle emission to 131Xe.9,29
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Figure 1 : Decay Schema of 131I (from Meller J. Sahlmann CO. Becker W. Radio-
iodine treatment of functional autonomy)9
3 emission is the principal - particle and carries an average energy of 0.61MeV
The majority of 131I (90%) decays to the 364keV (1), 7% to the 637keV (2) and
2% to the 723keV (3) excited level of 131Xe. All nuclei in the 723keV and 637keV
decay by -emission (2 + 3) directly to the ground state. Of the 364keV group, 7%
of nuclei decay via the 80keV level (4).28
Oral 131I is absorbed via the gastrointestinal tract vasculature and preferentially
taken up by the thyroid gland.27
131I is actively taken up by the thyroid follicular cell via the sodium-iodine symporter
on the basolateral membrane on the thyrocyte. Iodide is transported through the
intracellular space towards the apical cell surface, to the follicular lumen. This is
facilitated by the chloride-iodine transport protein, pendrin. Iodide undergoes
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oxidation to Iodine by thyroid peroxidase at the luminal surface of the apical
membrane of the epithelium.25
131I is a medium range - emitter with a range in thyroid tissue of 0.4-0.8mm. The -
particles produce more than 90% of the dose to the thyroid tissue whilst the 
emission is utilised in imaging modalities of the thyroid.27
In normal thyroid tissue, the follicular cells range in diameter from 0.05-0.50mm.
Hyperfunctioning thyrocytes have considerably smaller diameters (ranging from
0.075-0.15). Homogenous distribution on thyroid scans predicts a homogenous dose
distribution through the thyroid gland. The more vascular the gland, the better the
distribution of the dose.27
The biological effects of 131I and radiation in general, result from chemical changes
at the molecular level.7 These changes may be brought about directly or indirectly.
Direct action is produced by high linear energy transfer (LET) radiation. - particles
deposit their energy within macro-molecules, usually DNA, causing ionization and
excitation of the molecule, ultimately altering its conformation and function.28
Indirect action occurs when radiation interacts with other molecules or atoms to
produce free radicals (H.;OH.) which in-turn interact with DNA. Free radicals have an
outer-shell unpaired electron that is highly reactive. The simplest free radical is H-
which is active in an aqueous environment, a characteristic of thyroid follicular cells.
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DNA integrity is vital for cell survival. Free radicals interact with both the base and
sugar components of the DNA molecule. The OH. free radical reacts with bases by
the addition of a double bond and with the sugars by hydrogen ion abstraction.
These reactions induce DNA damage by :
 Breakage of hydrogen bonds resulting in structural damage.
 Loss of or change in nitrogenous bases which may be lethal or result in a
mutation.
 DNA single-strand breaks which may be repairable.
 DNA double-strand breaks which are invariably lethal.
 Cross-linking between 2 DNA molecules.
The net result of these interactions is cell death or functional impairment. 27,30
Histological findings in cells which have been exposed to 131I include epithelial
swelling and necrosis, oedema and leucocyte infiltration. Within two weeks of RAI
administration, there is follicular breakdown and disruption with leakage of
extracellular colloid. Fibrosis starts about three to four weeks later.29,30
Radiation thyroiditis is an entity that may occur one to three days after RAI therapy.
It is characterised by oedema, tenderness, hyperaemia, hyperthermia and
dysphagia. In this time interval, there may be a paradoxical rise in thyroid hormone
level. This flare phenomenon is usually due to the release of stored thyroid hormone
from damaged follicles. In its most severe form, this surge in thyroid hormone may
cause thyroid storm. The incidence in one large clinical study was 0.34%.15 Large
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goitres have the potential to cause local compressive symptoms on the trachea and
oesophagus, post-RAI. Retrosternal goitres may additionally give rise to superior
vena cava syndrome due to the acute inflammatory response. The use of RAI in
these settings is advocated, only in the presence of strict monitoring.24 The use of
lithium to potentiate the activity of RAI has largely fallen out of favour.31
Late changes due to RAI have been assessed by analyzing histopathological
specimens ranging from four months to twelve years post-RAI. These specimens
show marked fibrosis, follicular disruption and irregular hypoplastic follicles, with
associated eosinophilia and telangiectasia.32 The radiation fibrosis tends to be
progressive over the years. Regeneration of follicles tends to be sporadic, focal and
irregular. The neoplastic potential of this RAI damage has not proven to be
increased, when compared to the general population.2,29,30
Cell survival curves are important tools employed in radiobiology to illustrate dose-
response relationships.30
Due to the delivered dose being dependent on mean effective half-life, the cellular
effect of 131I is prolonged, with estimates suggesting that 95% of the total dose is
delivered within the first four weeks post-131I administration.28,30
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Dose Strategies for Radioactive Iodine
There are 3 approaches to selecting an optimal dose of RAI in patients with
Thyrotoxicosis.1,24,33,34 These include the fixed administered radioactivity method, the
prescribed radioactivity concentration method and the prescribed absorbed dose
method.
The Fixed Administered Radioactivity Method
This is also known as the Fixed Dose Method. A fixed radioactivity of 185-370MBq
(5-10mCi) is given to all patients irrespective of clinical, radiological or biochemical
variables.56 The doses mentioned have been validated in multiple clinical trials over
the last 20 years.6,10,17,36,37 A modification of the fixed dose method is the one that is
used at IALCH, where the dose selected for the individual patient is at the discretion
of the prescribing healthcare practitioner.36
The Prescribed Radioactivity Concentration Method
In this model, a fixed radioactivity per gram of thyroid tissue is chosen. This is
usually in the range of 55-110μCi/g in order to deliver a dose of 50-100Gy to the
thyroid. The administered radioactivity is calculated according to the gland size and
the percentage uptake of RAI at 24 hours in a tracer test. This method has been
proven in a few trials and is the preferred strategy at many centres. The following
formula is then used to determine the dose38 :
Activity (mCi) = (mCi/g x estimated gland mass (g) x 100) / (24hour % uptake)
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The Prescribed Absorbed Dose Method
The administered activity is calculated according to the following equation :
Activity (mCi) = (Prescribed absorbed dose x gland mass x 6.67) / (T½(eff) x 24hour % uptake)
Where the effective half-life of RAI, T½(eff) is given by the equation :
1/T½(eff) = 1/T½(phys) + 1/T½(bio)
A scintillation counter is required to determine the percentage uptake of RAI tracer.
The absolute uptake is difficult to measure and is considered to be a function of the
exponential decay of RAI – this in itself is not mono-exponential. As a result, a
relative uptake value is calculated over a 24 hour period.16,20 Additionally, medical
physicists have derived many complex radiobiological equations to try to make the
procedure more accurate. This process has proven to be very time-consuming,
inconvenient to the patient and costly, with minimal, if any clinical benefit.34,39 An
additional flaw in the calculated dose methodology is the estimation of thyroid gland
mass. Radio-isotope scans are inaccurate and there is significant clinician-clinician
variability in estimating gland mass, even amongst endocrinologists who have been
using this method.39,40
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Factors that Influence Outcome in RAI Therapy
Dose
A wide spectrum of clinical trials have demonstrated that higher doses of RAI are
invariably associated with a higher cure rate (euthyroidism), whilst also being
associated with a higher incidence of hypothyroidism.5,6,15,41,42,43,44
Radiosensitivity
The RAI dosage models described above attempt to tailor dose according to
individual patient requirements. Attempts to predict radiosensitivity, by measuring
uptake of RAI into thyrocytes, have not proven to be consistent or reproducible.
These strategies may over-simplify the actual biological behavior of the thyrotoxic
gland, but they remain popular throughout the world.20,34,38
Antithyroid Drugs (ATDs)
ATDs are often used in the initial management of GD. Many patients will achieve
euthyroidism on these drugs and can be maintained on them for a few years. Over
time, ATDs decelerate the uptake of iodine by the thyrocyte. This potentially reduces
the therapeutic effect of RAI when administered later in the clinical course of the
disease. As such, it is widely believed that ATDs may exert a radio-protective
effect.11 Studies have demonstrated that failure to stop ATDs within three days of




Patients with large goiters have been shown to have poorer response rates to RAI
therapy. The enlarged thyroid gland is often differentially radiosensitive and whilst
estimating size and weight of the gland may be valuable predictors theoretically,
these models may only be applicable in Graves’ Disease, where iodine uptake is
homogenous.6,49
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CHAPTER 4 : PATIENTS  AND  METHODS
AIM
The aim of the study was to undertake an audit of the use of Radioactive Iodine
(RAI) in the definitive management of thyrotoxicosis at Inkosi Albert Luthuli Central
Hospital (IALCH), the quarternary referral centre in  KwaZulu-Natal, South Africa.
OBJECTIVES
To determine:
 the incidence of clinical and biochemical cure (euthyroidism)
 the incidence of hypothyroidism post RAI
 the incidence of clinical & biochemical failure post RAI – defined as persistent
hyperthyroidism
 the optimal dose of RAI
METHOD
This is a retrospective observational study of adult patients (> 15 years old) with
thyrotoxicosis, referred for the first time to the Clinical Oncology Department at
Inkosi Albert Luthuli Central Hospital (IALCH) by the Endocrinology department in a
four year period between 01/01/2004 and 31/12/2007.
The study was approved by the research ethics committee and the postgraduate
education committee of the University of KwaZulu-Natal (BE116/08). IALCH is the
quarternary referral centre in the province of KwaZulu-Natal.
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Most patients were commenced on carbimazole on diagnosis of thyrotoxicosis whilst
awaiting definitive RAI therapy. The dose of RAI prescribed and administered was
clinician-dependent and within the recommended minimum and maximum doses.
Patients were followed-up at the Endocrinology clinic at IALCH. Response to RAI was
monitored using biochemical parameters (namely, serum Thyroid Stimulating
Hormone and Free T4 levels). Incidence of euthyroidism (cure), hypothyroidism and
hyperthyroidism (treatment failure) were correlated with dose of RAI. Patients were
followed-up for at least two years or until the onset of hypothyroidism. The follow-
up period was until 31/12/2007.
Data was collected and collated using Date Capture sheets (Appendix A)
Data collected included:
Demographic data: Age, gender
Clinical data: Aetiology, co-morbid cardiac disease
Biochemical data: Thyroid function tests
Immunological data: Thyroid antibodies (where available)
Radiological data: Radio-isotope scan (where available)
Dosimetric data: Dose of radioactive iodine, cumulative dose
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DEFINITION OF TREATMENT OUTCOMES
Euthyroidism§: normal level of serum thyroid hormone.
Hypothyroidism§: clinical condition of a deficit of thyroid hormone in the blood,
defined by serum TSH > 4.20mU/L, FT4 < 12.20pmol/L or FT3 < 3.50pmol/L ¥
Hyperthyroidism§: clinical condition of increased thyroid hormone in the blood,
defined by serum TSH < 0.10mU/L, FT4 > 22.70pmol/L or FT3 > 6.50pmol/L ¥
(§Outcome assessed in the absence of medical therapy i.e. carbimazole or thyroxine;
¥Reference laboratory values at IALCH)
STATISTICAL  ANALYSIS
Statistical analysis was undertaken using SPSS Version 15.0. (SPSS Inc, Chicago, Ill,
USA). Mean ± SD was used for continuous variables. A p-value of < 0.05 was
considered to be statistically significant and 95% confidence intervals were also
reported where appropriate. For multiple (intergroup) comparisons, Bonferroni’s test,
oneway analysis of variance (ANOVA), inverse chi-square testing and Levene’s tests
were used.
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CHAPTER 5 : RESULTS
5.1  Total Study Group Baseline Characteristics
A total of 302 patients with thyrotoxicosis were treated with RAI during the defined
study period (01 January 2004 - 31 December 2007). These constituted referrals
from the Endocrinology Clinic at IALCH, Addington Hospital, RK Khan Thyroid Clinic
and external sources.
Of the 302 patients treated, only 114 (37.7%) patients met the inclusion criteria for
this retrospective study and they form the “total study group”.
The inclusion criteria were :
- New referral to the Oncology Clinic
- Age > 15
- Follow-up for at least two years after the first dose of RAI or until the onset of
hypothyroidism
The remaining 188 patients were either lost to follow-up or continued their follow-up
at their referral hospital.
Table 1 shows the baseline characteristics of the study group (n = 114). The
majority of the patients were female, accounting for 97 (85.1%), whilst there were
17 (14.9%) males. Ninety-six (84.2%) patients had GD, 15 (13.2%) had toxic MNG
and there were three (2.6%) patients with TA. Cardiac disease was documented in
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25 patients (21.9%). Eighty-eight (77.2%) patients had pretreatment with the ATD,
carbimazole.







Mean age (years) 46.1 ± 13.8
Diagnosis
Graves disease (GD)
















At two year follow-up, ten patients (8.8%) were euthyroid, 91 (79.8%) were
hypothyroid and 13 (11.4%) hyperthyroid. Amongst the 17 male patients, at
minimum of two years of follow-up, 16 were hypothyroid and one patient remained
hyperthyroid. Amongst the females, 75 patients (77.3%) were hypothyroid, ten
(10.3%) were euthyroid and 12 (12.4%) were hyperthyroid. (Figure 2)
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Figure 2 : Two year follow-up status in the total study group (n = 114)
Thirty-one (27.2%) patients remained persistently hyperthyroid after the first dose
of RAI and required repeated doses of RAI; these were deemed to represent
treatment failures.
5.3 RAI dose requirements
The initial dose prescribing patterns at the centre range from 5 – 12mCi (Table 2)
with a mean initial dose of 8.5 ± 1.4 mCi . Thirty-one (27.2%) patients remained
hyperthyroid after the initial dose of RAI and required a second dose of RAI, six
patients required a third dose, one patient a fourth dose and one patient received




Table 2 : Initial RAI dose requirements in the study group (n=114)








The cumulative dose of RAI prescribed ranged from 5 - 46mCi, with a mean dose of
11.0 ± 5.5 mCi.
5.4 Outcomes
Table 3 summarizes treatment outcomes at two year follow-up, based on the
aetiology of thyrotoxicosis
Table 3 : Treatment outcomes at two year follow-up, based on aetiology (n = 114)
Aetiology Euthyroid Hypothyroid Hyperthyroid
Graves’ disease (n = 96) 7 (7.3%) 83 (86.5%) 6 (6.2%)
Multinodular goiter (n = 15) 2 (13.3%) 8 (53.3%) 5 (33.3%)
Toxic adenoma (n = 3) 1 (33.3%) 0 2 (66.7%)
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Of the 96 patients with GD, 17 were male and 79 female. The mean age of the male
patients was 40.6 years (17-66), whilst the mean age for female patients was 45.6
years (18-79). The mean dose of RAI prescribed was 10.8mCi (5-46mCi). At two
year follow-up, seven patients (7.3%) were euthyroid, 83 (86.5%) were hypothyroid
and six (6.2%) patients remained hyperthyroid.
There were 15 patients with MNGs, all of whom were female. Mean age was 54.4
years (36-76). The mean administered dose of RAI was 13.3mCi (5-24mCi). At a
minimum of two years of follow-up, two patients (13.3%) were euthyroid, 8 (53.3%)
were hypothyroid and five patients (33.3%) remained hyperthyroid.
In the three patients that had TAs, the dose of RAI administered, ranged from 8-
15mCi, with a mean dose of 10.3mCi. One patient was euthyroid and two patients
remained hyperthyroid at two year follow-up.
Time and dose requirements for euthyroidism
Analysis of the time and dose required to achieve euthyroidism was done, based on
aetiology of the thyrotoxicosis. Only one patient with TA achieved euthyroidism –
she received 8mCi and was euthyroid after eight months. Ten patients with MNG
achieved a euthyroid state, eight of whom subsequently developed hypothyroidism
at two year follow-up. They received a mean dose of 12mCi (5-24mCi) and the mean
time to euthyroidism was 12.5 months (3-27 months). Ninety patients with GD
became euthyroid after RAI, with 83 eventually becoming hypothyroid, in the
absence of medical therapy. Of the 17 males treated, the mean dose of RAI was
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9.6mCi (7-20mCi) and the mean time to euthyroidism was 5.2 months (1-28
months). Seventy-three female patients with GD became euthyroid during follow-up.
The mean dose of RAI was 9.8mCi (5-20mCi) and the mean time to euthyroidism
was 5.8 months. Six patients with GD were still hyperthyroid after the minimum
two year follow-up. The mean dose of RAI administered, was 23.7mCi (10-46mCi).
Five patients with toxic MNG remained hyperthyroid despite repeated doses of RAI.
The mean cumulative dose prescribed was 17mCi (14-21mCi). For the purposes of
data analysis, TA & MNG patients were grouped together as “Toxic Nodular Disease”
(TND). The mean time to euthyroidism for TND was 10.0 months. In those patients
with TND who became hypothyroid, the mean time was 9.1 months.
5.4.1  Analysis by dose of RAI
Table 4 depicts the stratification of patient characteristics and outcomes according to
the prescribed dose i.e. into Low dose (≤ 7.5mCi), Intermediate dose (8-9mCi) and
High dose (≥ 10mCi).
There were no significant differences in the dose of RAI prescribed, based on age,
gender, the presence or absence of cardiac disease or pre-treatment with ATDs.
(Appendix B, Tables I – IV)
In contrast, there were significant differences in the doses prescribed, based on the
baseline TSH, FT4 and FT3. Subjects who were prescribed a high dose of RAI, had
significantly higher baseline TSH, FT4 and FT3, when compared to those who were
prescribed a low dose of RAI. They also had a significantly higher FT4 and FT3 when
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compared to those patients who were given an intermediate dose of RAI. No
difference in baseline TFTs was observed between the groups who received a low
dose or intermediate dose of RAI. (Tables 4 - 8)
The dose of RAI that was prescribed had no significant effect on the incidence of
euthyroidism, hypothyroidism or hyperthyroidism, nor did it have an effect on the
time taken to attain euthyroidism or hypothyroidism in those patients who were
cured. (Appendix B, Tables V – XI)
For the subjects who received a low dose of RAI, none achieved euthyroidism.
Eighty-eight percent (88%) of patients who received a low dose of RAI became
hypothyroid and 12% remained hyperthyroid.
For those patients given an intermediate dose of RAI, the rates of euthyroidism,
hypothyroidism and hyperthyroidism were 14.3%, 77.5% and 8.2% respectively.
Amongst those patients given a high dose of RAI, 7.5% were euthyroid, 77.5%
became hypothyroid and 15% remained hyperthyroid.
Table 4 also shows the mean cumulative doses of RAI eventually prescribed, for
patients receiving an initial low, intermediate and high dose of RAI. As expected the
difference in total dose between the three dose groups was significant. Details of
intergroup analysis by ANOVA and Bonferroni tests are shown in Tables 9 and 10.
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Table 4 : Stratification by prescribed dose of RAI in the total study group (n = 114)
Mean ± SD unless otherwise stated. * p values using ANOVA or chi-square test. § vs high dose, p < 0.05 using Bonferroni’s test. ¥ vs high dose, p < 0.01 using
Bonferroni’s test. ATD : Anti-thyroid drug.
RAI Dose (mCi)
Total







Female n(%) 97 (85.1%) 22 (88%) 42 (85.7%) 33 (82.5%)
Male n(%) 17 (14.9%) 3 (12%) 7 (14.3%) 7 (17.5%) 0.8
Age 46.1 ± 13.8 46.7 ± 18.0 45.7 ± 12.4 46.3 ± 12.7 0.9
Cardiac n(%) 25 (21.9%) 5 (20%) 9 (18.4%) 11 (27.5%) 0.6
ATD n(%) 88 (77.2%) 17 (68%) 38 (77.6%) 33 (82.5%) 0.4
Baseline TFT
TSH (mU/L) 1.1 ± 4.8 3.1 ± 8.9§ 0.1 ± 3.4 0.01 ± 0.5 0.05 0.01 - 5.83
FT4 (pmol/L) 43.9 ± 30.1 34.8 ± 30.3§ 38.0 ± 26.0¥ 56.9 ± 30.9 0.003 3.91 - 39.87
FT3 (pmol/L) 16.8 ± 13.3 12.6 ± 11.5¥ 14.0 ± 11.1¥ 22.8 ± 14.9 0.001 2.22 - 17.98
Total Dose (mCi) 11.02 ± 5.51 8.74 ± 3.9¥ 10.2 ± 4.25§ 13.4 ± 6.8 0.001 0.49 - 7.93
Follow-up thyroid status (%)
Hyperthyroid 13 (11.4%) 3 (12%) 4 (8.2%) 6 (15%) 0.6
Euthyroid 10 (8.8%) 0 7 (14.3%) 3 (7.5%) 0.1
Hypothyroid 91 (79.8%) 22 (88%) 38 (77.5%) 31 (77.5%) 0.5
Time (months) to
Euthyroid 5.9 ± 5.7 4.8 ± 4.8 6.2 ± 6.2 6.2 ± 5.6 0.6 2.26 - 5.16
Hypothyroid 9.9 ± 8.3 9.0 ± 7.1 9.9 ± 8.6 10.4 ± 8.7 0.8 4.18 - 7.06
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Table 5 : Intergroup analysis based on prescribed dose of RAI - ANOVA (TFTs)
Sum of Squares df Mean Square F Sig.
TSH Between Groups 136.026 2 68.013 3.079 .050
Within Groups 2451.686 111 22.087
Total 2587.712 113
FT4 Between Groups 10455.532 2 5227.766 6.319 .003
Within Groups 91830.878 111 827.305
Total 102286.410 113
FT3 Between Groups 2244.643 2 1122.322 7.043 .001
Within Groups 17688.774 111 159.358
Total 19933.417 113
Table 6 : Intergroups analysis based on prescribed dose of RAI - Bonferroni Tests
(TSH)





Low Intermediate 2.22191 1.15510 .171 -5.589 5.0297
High 2.71740 1.19820 .049 .0048 5.8300
Intermediate Low -2.22191 1.15510 .171 -5.0297 .5859
High .69549 1.00147 1.000 -1.7389 3.1299
High Low -2.71740 1.19820 .049 -5.8300 -.0048
Intermediate -.69549 1.00147 1.000 -3.1299 1.7389
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Table 7 : Intergroup analysis based on prescribed dose of RAI - Bonferroni Tests
(FT4)





Low Intermediate -3.23156 7.06937 1.000 -20.4158 13.9527
High -22.04010 7.33313 .010 -39.8655 -4.2147
Intermediate Low 3.23156 7.06937 1.000 -13.9527 20.4158
High -18.80854 6.12914 .008 -33.7073 -3.9098
High Low -22.04010 7.33313 .010 4.2147 39.8655
Intermediate 18.80854 6.12914 .008 3.9098 33.7073
Table 8 : Intergroup analysis based on prescribed dose of RAI - Bonferroni Tests
(FT3)





Low Intermediate -1.40737 3.10267 1.000 -8.9493 6.1346
High -10.16155 3.21843 .006 -17.9849 -2.3382
Intermediate Low 1.40737 3.10267 1.000 -6.1346 8.9493
High -8.75418 2.69001 .005 -15.2931 -2.2153
High Low 10.16155 3.21843 .006 2.3382 17.9849
Intermediate 8.75418 2.69001 .005 2.2153 15.2931
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Table 9 : Intergroup analysis based on prescribed dose of RAI - ANOVA (Total Dose)
Sum of Squares df Mean Square F Sig.
Between Groups 392.330 2 196.165 7.158 .001
Within Groups 3041.866 111 27.404
Total 3434.195 113
Table 10 : Intergroup analysis based on prescribed dose of RAI - Bonferroni Tests
(Total Dose)





Low Intermediate -1.484 1.287 .753 -4.61 1.64
High -4.685 1.335 .002 -7.93 -1.44
Intermediate Low 1.484 1.287 .753 -1.64 4.61
High -3.201 1.116 .015 -5.91 -.49
High Low 4.685 1.335 .002 1.44 7.93
Intermediate 3.201 1.116 .015 .49 5.91
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5.4.2 Analysis by aetiology
Table 11 stratifies the patient cohort according to the aetiology of their
thyrotoxicosis.
The difference in gender distribution between patients with GD and TND, was not
statistically significant. (Appendix B, Table XII) Patients with TND were significantly
older (54.0 ± 12.3) than those with GD (44.7 ± 13.6), p = 0.008. (Table 12)
Patients with GD had a higher baseline FT4 (45.92pmol/L vs 33.33pmol/L, p = 0.04)
and FT3 (17.83pmol/L vs 11.33pmol/L, p = 0.006). The difference in mean TSH
levels between the two groups, was not significant. (Table 13)
There was no significant difference in the mean first dose of RAI (GD vs. TND :
8.6mCi  vs. 7.9mCi) nor in the total dose of RAI that was prescribed for either GD
(10.7mCi) or TND (12.8mCi). (Appendix B, Table XIII)
Euthyroidism was achieved in 5.2% of patients with GD and 27.8% of those with
TND (p = 0.009). There was a significantly higher incidence of hypothyroidism
amongst patients with GD (88.5% vs 33.3%, p < 0.001). The incidence of
hyperthyroidism was significantly higher in patients with TND (38.9%) than in those
with GD (6.3%) (p = 0.001). (Table 14 – 16)
Patients with GD had a mean time to euthyroidism of 5.38 months and time to
hypothyroidism of 9.94 months. For those with TND, the mean time to euthyroidism
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was 10.00 months, whilst mean time to hypothyroidism was 9.14 months; However,
there was no significant difference between the two groups. (Appendix B, Table XIV)
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Female n(%) 97 (85.1%) 79 (82.3%) 18 (100%)
Male n(%) 17 (14.9%) 17 (17.7%) 0 0.1
Age (years) 46.1 ± 13.8 44.7 ± 13.6 54.0 ± 12.3 0.008
TSH (mU/L) 1.07 ± 4.8 1.23 ± 5.2 0.18 ± 0.7 0.4 1.4 - 3.5
FT4 (pmol/L) 43.9 ± 30.1 45.9 ± 31.3 33.3 ± 20.5 0.04¥ 0.8- 24.3
FT3 (pmol/L) 16.8 ± 13.3 17.8 ± 13.9 11.3 ± 7.4 0.006 2.0 - 11.0
1st Dose (mCi) 8.6 ± 1.3 7.9 ± 1.2 0.1 0.04 - 1.3
Total Dose (mCi) 11.0 ± 5.5 10.7 ± 5.4 12.8 ± 6.0 0.1 0.6 - 4.9
At follow-up
Hyperthyroid n(%) 13 (11.4%) 6 (6.3%) 7 (38.9%) 0.001
Euthyroid n(%) 10 (8.8%) 5 (5.2%) 5 (27.8%) 0.009
Hypothyroid n(%) 91 (79.8%) 85 (88.5%) 6 (33.3%) <0.001
Time (months) to
Euthyroid 5.9 ± 5.7 5.4 ± 5.0 10.0 ± 9.0 0.1 1.5 - 10.7
Hypothyroid 9.9 ± 8.3 9.9 ± 8.3 9.1 ± 8.5 0.8 5.7 - 7.2
Mean ± SD, except where stated. * p values using ANOVA or chi-square test. ¥ Confidence interval crosses unity, so comparison not significant
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Mean Difference Std Error
Difference
t-test for Equality of Means
95% CI
F Sig. t df Lower Upper
Equal Variances
Assumed .080 .778 -2.175 112 .008 -9.354 3.446 -16.181 -2.527
Equal Variances
Not Assumed -2.915 25.503 .007 -9.354 3.209 -15.956 -2.752
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Table 13 : Independent samples test based on aetiology (TFTs)
Levene’s Test for
Equality of Variances
t-test  for Equality of Means
95% CI









2.563 .112 .853 112 .396 1.04955 1.23062 -1.38877 3.48786
Equal variances
not assumed 1.887 108.96
8
.062 1.04955 .55624 -.05290 2.15199
FT4
Equal variances
assumed 7.712 .006 1.641 112 .104 12.58670 7.67047 -2.61134 27.78475
Equal variances
not assumed 2.176 33.925 .037 12.58670 5.78524 .82873 24.34467
FT3
Equal variances
assumed 7.647 .007 1.927 112 .057 6.49486 3.37119 -.18471 13.17443
Equal variances
not assumed 2.889 43.546 .006 6.49486 2.24829 1.96239 11.02734
38
Table 14 : Chi-square tests based on aetiology (Hyperthyroidism)






Pearson Chi-Square 15.983a 1 .000
Continuity Correctionb 12.916 1 .000
Likelihood Ratio 11.965 1 .001




N of Valid Cases 114
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.05
b. Computed only for a 2x2 table
Table 15 : Chi-square tests based on aetiology (Euthyroidism)






Pearson Chi-Square 9.648a 1 .002
Continuity Correctionb 7.034 1 .008
Likelihood Ratio 7.214 1 .007




N of Valid Cases 114
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 1.58
b. Computed only for a 2x2 table
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Table 16 : Chi-square tests based on aetiology (Hypothyroidism)






Pearson Chi-Square 28.687a 1 .000
Continuity Correctionb 25.362 1 .000
Likelihood Ratio 23.379 1 .000




N of Valid Cases 114
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.63
b. Computed only for a 2x2 table
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5.4.3 Analysis of treatment outcomes
Table 17 outlines the baseline characteristics based on treatment outcome at follow-
up.
Ninety-six patients had GD, whilst the remaining 18 had TND. There was a
significant overall difference for treatment outcomes between the group with GD and
that with TND (p < 0.001). Intergroup analysis (Table 17) showed that the majority
of GD patients (88.5%) became hypothyroid, whilst hypothyroidism only occurred in
33.3% (6/18) of TND patients. Only 6.3% (6/96) of GD patients remained
persistently hyperthyroid whilst 38.9% (7/18) of TND patients failed RAI therapy.
There were no significant predictive factors for treatment outcome amongst the
variables analyzed in this cohort of patients (gender, age, cardiac status, use of
ATDs, baseline TFT and dose of RAI). (Appendix B, Tables XV – XXV)
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Table 17 : Baseline characteristics of study group based on disease outcomes at 2 year follow-up
Mean ± SD, except where stated. * p values using ANOVA or chi-square test.









Female  n(%) 97 (85.1%) 10 (100%) 75 (82.4%) 12 (92.3%)
Male  n(%) 17 (14.9%) 0 16 (17.6%) 1 (7.7%) 0.2
Age 46.1 ± 13.8 45.6 ± 14.6 45.4 ± 13.8 51.7 ± 13.1 0.3
Graves Disease   n(%) 96 (84.2%) 5 (50%) 85 (93.4%) 6 (46.2%)
Toxic Nodular Disease  n(%) 18 (15.8%) 5 (50%) 6 (6.6%) 7 (53.8%) 0.000
Cardiac  n(%) 25 (21.9%) 3 (30%) 17 (18.7%) 5 (38.5%) 0.2
Carbimazole  (n%) 88 (77.2%) 7 (70%) 73 (80.2%) 8 (61.5%) 0.3
TSH (mU/L) 1.1 ± 4.8 0.3 ± 0.9 1.3 ± 5.3 0.7 ± 0.2 0.6
FT4 (pmol/L) 43.9 ± 30.1 41.7 ± 26.5 43.2 ± 29.9 50.7 ± 35.3 0.7
FT3 (pmol/L) 16.8 ± 13.3 14.6 ± 12.1 16.3 ± 12.7 22.1 ± 17.5 0.3
Dose of RAI
Low  n(%) 25 0 22 (24.2%) 3 (23.1%)
Intermediate  n(%) 49 7 (70%) 38 (41.7%) 4 (30.7%)
High  n(%) 40 3 (30%) 31 (34.1%) 6 (46.2%) 0.3
Total Dose (mCi) 11.0 ± 5.5 12.4 ± 5.4 9.7 ± 3.4 19.4 ± 9.4 0.2
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Table 18 : Chi-square Tests based on disease outcomes (Aetiology)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 28.750a 2 .000
Likelihood Ratio 23.413 2 .000
Linear-by-Linear Association 23.849 1 .000
N of Valid Cases 114
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 1.58
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CHAPTER 6 : DISCUSSION
Although RAI has been in clinical use for over 70 years, there remains no consensus
on the optimal dose that is required to cure patients. Whilst most clinicians consider
hypothyroidism to be an acceptable, unavoidable end-point, others consider it to be
a side-effect.6,35,43 This study was undertaken with the aim of evaluating the
treatment outcomes at the local centre, in the hope of offering some guidelines for
the initial and total dose of RAI to be administered.
A major issue highlighted in this study, is the poor patient follow-up. Three hundred
and two (302) patients received RAI during the defined study period. Only 114
(37.7%) met the inclusion criteria, largely on the basis of not being followed-up at
the treatment centre. This factor remains a challenge that is well-documented by
similar studies in developing countries.10,31,36,50,51
Thyroidectomy and ATDs are recognized modalities in the management of
thyrotoxicosis. Torring et al. randomised 179 patients with GD to receive either
ATDs, surgery or RAI. Medically treated patients were at highest risk of relapse.
However, a high failure rate (38%) was found in the RAI arm, although there was a
high patient satisfaction rate for all modalities, assessed by quality of life
questionnaires.21 The cost and morbidity associated with surgery means that ATDs
and RAI are the preferred therapeutic modalities at most centres in the world.1,24
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From the available literature, the prevalence of thyrotoxicosis in the general
population is estimated at 2% in women and 0.2% in males,29 with GD being the
commonest cause of thyrotoxicosis in iodine-sufficient areas.1,34 In this study, GD
accounted for 84.2% of all cases. The finding of a female preponderance (85.1%) is
comparable with that reported in the literature. There was a larger cohort of cardiac
patients (21.9%) in this study, when compared to reported rates of thyrocardiac
disease that range between 2-20% (12.1% in the study by Kwok et al).40 This may
be accounted for by the late presentation of patients in the local public health
sector.
The cure rate after the first dose of RAI (72.8%) in this study is comparable with
available reports (which predominantly evaluated GD), which cite success rates of 60
– 92%.1,12,36 The overall GD cure rate at two year follow-up was 95.7%. Patients
who failed to respond to an initial dose of RAI, were offered a repeat dose. The use
of repeated doses of RAI is a validated treatment option, both in terms of safety and
efficacy.2,52 Metso et al. reported that 25% of their patient cohort of 2043 patients
required repeated doses of RAI, with no significant increase in morbidity.29
Early hypothyroidism rates for RAI therapy in GD range from 20 - 76% and 11 -
34% for Toxic MNG.2,5,6,8,15,19,23,25,29 Nygaard and colleagues reported a 92% cure
rate for Danish patients with MNG with a five year hypothyroidism rate of only 14%;
the median dose used was 370MBq (10mCi).23 In contrast, the outcomes of patients
with TND in this study, were less impressive with a treatment failure rate of 39.9%
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and a hypothyroidism rate of 33.3%. There was no significant difference between
the doses of RAI that were prescribed for patients with GD and those with TND.
The finding that more than one-third of patients with GD in this study developed
hypothyroidism is consistent with those documented in most studies that included a
heterogenous population of thyrotoxic patients.5,6,8,10,17,25,29,40,49
RAI dose is considered to be a significant contributing factor for the development of
hypothyroidism.6,35 However, in this study there was no direct correlation between
RAI dose and therapeutic outcome or on the time to achieve a cure. This is validated
in other studies that made a similar observation.6,10,17,25,29,40,41 There are however,
other confounding studies that suggest that a high dose of RAI results in
significantly higher cure rates, albeit with a higher rate of hypothyroidism.2,5,8,16,41
Not all studies that used a higher dose of RAI, demonstrated a higher rate of
hypothyroidism.1,25,40
In this study, the dose of RAI prescribed was according to a modified fixed-dose
method that was dependent on the attending Clinical Oncologist.2,5,8,16,41 The only
significant factor that influenced the decision on the dose of RAI that was
administered was the patient’s baseline thyroid function tests. Those patients who
received a high dose of RAI had a significantly higher baseline TSH, FT4 and FT3
than those who received a low dose of RAI.
From available literature, reports of cure rates with fixed dose RAI have been
variable.10,35,42,51,54 Alexander et al. used a fixed dose of 8mCi of RAI and reported an
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impressive cure rate of 86%.35 In a weight-adjusted retrospective study by Bastan-
Hagh et al. there was a 91.2% cure rate, with 57.7% of patients being rendered
hypothyroid.10
Sankar et al. conducted a prospective study to assess their practice of empirical low-
dose RAI, with the aim of trying to avoid hypothyroidism. Of the 174 patients
evaluated at one year follow-up, 16.7% were euthyroid, 29.3% hypothyroid and
54% remained persistently hyperthyroid. Those patients who failed RAI therapy
received a significantly lower dose and the authors concluded that their policy of
empirical low-dose RAI needed to be changed, to increase the cure rate.51
In one of the few South African studies undertaken on doses of RAI and outcomes,
Kalk et al. reported on 150 patients who were treated with low dose (mean 2.8mCi)
and moderate dose RAI (mean 5.9mCi). At one year follow-up, there was an
unacceptably high rate of persistent hyperthyroidism (39%) in patients who received
low dose RAI, as opposed to 19% for the moderate dose. The conclusion was that
low dose RAI is unsuitable for the management of thyrotoxicosis.42 This was further
validated in a British study by Hoskin, which showed no benefit of using fixed low
dose RAI.54
The three different methods of determining RAI dose (fixed dose, calculated dose
and absorbed dose), have been the subject of many published reports. Several
studies have shown that calculated doses of RAI do not have any benefit over fixed
doses, in terms of cure rate.25,40 Although low fixed doses are associated with low
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rates of hypothyroidism, they result in low cure rates.22 A French study by Catargi
and colleagues analyzed the effectiveness of individual dosimetric calculation. They
established that delivered doses to the thyroid were highly variable and
unpredictable and recommended that calculated RAI doses be abandoned in favour
of the fixed dose method.39
The fixed dose RAI method has been shown to be equivalent to the prescribed
radioactivity concentration method and the prescribed absorbed dose method, in
terms of treatment outcome.1,36,38,39 The fixed dose method is however simple,
reproducible and more cost-effective and is therefore used at the local hospital and
at most centres worldwide.1,6,25,27,29,40
Kwok et al. reported results from a study in 2000 that utilized a fixed dose of RAI in
149 patients. The treatment success rate was 66%. Patients who used ATDs were at
a higher risk of treatment failure. The rate of hypothyroidism at three year follow-up
was 73%. The use of fixed dose RAI was much less resource-intensive, more cost-
effective and more user-friendly and was recommended as a routine practice.40,58
There were no significant predictors of outcome to RAI therapy identified in this
study.
Numerous attempts have been made to identify predictors of outcome in the use of
RAI. Allabadhia et al. reported that in patients with GD, those with large goitres,
severe biochemical disease, men and younger patients were less likely to respond to
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a single dose of RAI.6 Additional poor prognostic factors include high 24 hour thyroid
123I uptake value and pretreatment with ATDs for more than four months.4,35
Younger patients tend to have more severe hyperthyroidism at presentation.8,55
Yamashita et al. reported that younger patients were more likely to have persistent
hyperthyroidism after RAI therapy and require higher doses of RAI, than older
patients.56 This factor was not analyzed in this study.
In a retrospective study from the Mayo Clinic, the authors reported that the
following factors predicted higher rates of hypothyroidism : age < 40 years, pre-
treatment with ATDs, higher dose of RAI and smaller estimated thyroid gland size.8
Although patients in this study who developed hypothyroidism were younger, this
was not statistically significant.
The results of this study which showed no significant predictors of outcome to RAI,
may be accounted for by the small sample size, the retrospective nature of the study
or the fact that crucial variables may not have been analysed or were missing (eg.
thyroid volume and RAI uptake).
Regarding the impact of pretreatment with ATDs, in this study, patients who were
pre-treated with carbimazole did not display any difference in outcome compared to
those who were not given carbimazole. Similar observations were reported by
Andrade and colleagues, who showed that ATD use had no effect on both cure and
hypothyroidism.57 In contrast, Sabri et al. reported a success rate of 93% vs. 49%
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(p < 0.001) in favour of those not pre-treated with ATDs,47 as did a Danish study
which showed that the use of propylthiouracil as pre-treatment resulted in a reduced
cure rate.46 On the other hand, a Swiss study demonstrated that stopping ATDs at
least three days prior to RAI therapy, did not negatively impact on cure rates.48
Although outcomes between ethnic groups was not analyzed as part of this study,
Kalk et al. reported definite differences in terms of presentation between white and
African (black) patients with hyperthyroidism. In their study, African patients
presented more frequently with more severe thyrotoxicosis, cardiac disease and
infiltrative ophthalmopathy. The observed differences were postulated to be due to
African patients presenting much later which was attributed to possible differences in
awareness of the disease, based on education, cultural beliefs and economic
factors.3
Studies conducted prior to the 1990s suggested a preference for medical therapy
and surgery over RAI, due to safety concerns, especially the perceived increased risk
of cancer, infertility and teratogenicity. Read et al. published data of a 36 year
retrospective analysis that confirmed the safety and efficacy of RAI used in 116
patients younger than 20 years old at initial diagnosis.59
Large epidemiological studies undertaken in the UK, USA and Sweden, demonstrated
a small relative increase in risk of diagnosis and mortality from thyroid cancer in
patients treated with RAI. Extensive follow-up of these studies seem to suggest that
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the risk is related to underlying thyroid disease rather than RAI therapy.60 This study
has too short a follow-up duration to assess for carcinogenicity.
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CHAPTER 7 : CONCLUSION
RAI has an established role in the management of thyrotoxicosis, as it is clinically
safe and cost-effective, when compared with other treatment modalities. It is
generally considered to be the gold-standard, but the ideal dosing strategy remains
an area of great controversy.
Although the three available strategies have benefits and limitations, none has been
shown to be superior in predicting the efficacy and outcomes of RAI therapy. The
strategy followed at IALCH, is the fixed-dose method (although in reality, the dose
varied according to individual discretion) and the data presented (in terms of cure
and treatment failure rates) compares favourably with reported data from other
centres worldwide.
This study shows that regardless of dose, the majority of patients eventually become
hypothyroid. Historical and contemporary studies advocate abandoning the use of
low doses of RAI due to unacceptably high rates of treatment failure. The reported
treatment failure rate in this study was 27.2% which although comparable with
other studies must be appreciated in the context of poor patient attendance at
follow-up.
The lack of significant identifiable predictive factors, the almost inevitable outcome
of hypothyroidism and the relative safety of RAI, presents a strong argument in
favour of using a high dose of RAI (10mCi) at the outset, in order to maximize the
52
chance of a cure, particularly in the setting of high rates of poor follow-up in the
local public healthcare system.
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APPENDIX  B
1. Analysis by dose-stratification
1.1 Baseline Characteristics (Chapter 5, Page 27)
Table I : Chi-squared tests based on prescribed dose of RAI (Gender)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square .393a 2 .821
Likelihood Ratio .394 2 .821
N of Valid Cases 114
a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 3.73
Table II : ANOVA based on prescribed dose of RAI (Age)
Sum of Squares df Mean Square F Sig.
Between Groups 15.790 2 7.895 .041 .960
Within Groups 21466.491 111 193.392
Total 21482.281 113
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Table III : Chi-square tests based on prescribed dose of RAI (Cardiac)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 1.143a 2 .565
Likelihood Ratio 1.121 2 .571
Linear-by-Linear Association .675 1 .411
N of Valid Cases 114
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.48
Table IV : Chi-square tests based on prescribed dose of RAI (Carbimazole)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 1.844a 2 .398
Likelihood Ratio 1.791 2 .408
Linear-by-Linear Association 1.746 1 .186
N of Valid Cases 114
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.48
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1.2 Outcomes (Chapter 5, Page 28)
Table V : Chi-square tests based on prescribed dose of RAI (Euthyroidism)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 4.346a 2 .114
Likelihood Ratio 6.266 2 .044
Linear-by-Linear Association .557 1 .455
N of Valid Cases 114
a. 3 cells (50.0%) have expected count less than 5. The minimum expected count is 2.19
Table VI : Chi-squared tests based on prescribed dose of RAI (Hypothyroidism)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 1.329a 2 .515
Likelihood Ratio 1.457 2 .483
Linear-by-Linear Association .864 1 .353
N of Valid Cases 114
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.04
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Table VII : Chi-square tests based on prescribed dose of RAI  (Hyperthyroidism)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 1.030a 2 .597
Likelihood Ratio 1.039 2 .595
Linear-by-Linear Association .259 1 .611
N of Valid Cases 114
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 2.85
1.3 Time to euthyroidism and hypothyroidism
Table VIII : ANOV A based on prescribed dose of RAI (Euthyroidism)
Sum of Squares df Mean Square F Sig.
Between Groups 31.783 2 15.891 .487 .616
Within Groups 3194.792 98 32.600
Total 3226.574 100
Table IX : ANOV A based on prescribed dose of RAI (Hypothyroidism)
Sum of Squares df Mean Square F Sig.
Between Groups 27.2055 2 13.527 .196 .823
Within Groups 6226.644 90 69.185
Total 6253.699 92
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Table X : Intergroup analysis Bonferroni tests (Time to euthyroidism)





Low Intermediate -1.360 1.485 1.000 -4.98 2.26
High -1.358 1.562 1.000 -5.16 2.45
Intermediate Low 1.360 1.485 1.000 -2.26 4.98
High .001 1.297 1.000 -3.16 3.16
High Low 1.358 1.562 1.000 -2.45 5.16
Intermediate -.001 1.297 1.000 -3.16 3.16
Table XI : Intergroup analysis Bonferroni tests (Time to hypothyroidism)





Low Intermediate -.923 2.218 1.000 -6.33 4.49
High -1.438 2.304 1.000 -7.06 4.18
Intermediate Low .923 2.218 1.000 -4.49 6.33
High -.514 1.984 1.000 -5.35 4.33
High Low 1.438 2.304 1.000 -4.18 7.06
Intermediate .514 1.984 1.000 -4.33 5.35
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2. Analysis by aetiology
2.1 Baseline characteristics (Chapter 5, Page 33)
Table XII : Chi-Square tests based on aetiology (Gender)






Pearson Chi-Square 3.746a 1 .053
Continuity Correctionb 2.480 1 .115
Likelihood Ratio 6.377 1 .12
Fisher’s Exact test .070 .042
N of Valid Cases 114
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.68
b. Computed only for a 2x2 table
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Table XIII : Independent Samples Test based on aetiology (Dose of RAI)
Levene’s Test for
Equality of Variances
t-test  for Equality of Means
95% CI











5.910 .017 1.855 112 .066 .6128 .3304 -.0419 1.2676
Equal variances not
assumed





2.879 .093 -1.528 112 .129 -2.151 1.408 -4.940 .638
Equal variances not
assumed
-1.421 22.466 .169 -2.151 1.514 -5.286 .984
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2.2 Time to euthyroidism and hypothyroidism (Chapter 5, Page 33)
Table XIV : Independent Samples Test based on aetiology (Time to euthyroidism and hypothyroidism)
Levene’s Test for
Equality of Variances
t-test  for Equality of Means
95% CI







Time to Euthyroid Equal variances
assumed
11.776 .001 -2.621 99 .010 -4.622 1.763 -8.121 -1.123
Equal variances not
assumed





.054 .817 .245 91 .807 .799 3.257 -5.671 7.269
Equal variances not
assumed
.239 6.954 .818 .799 3.339 -7.107 8.705
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3. Analysis by disease outcomes
3.1 Baseline characteristics (Chapter 5, Page 40)
Table XV : Outcomes based on gender
Euthyroid Hyperthyroid Hypothyroid Total
Gender F 10 (10.3%) 12 (12.4%) 75 (77.3%) 97 (100%)
M 0 1 (5.9%) 16 (94.1%) 17 (100%)
Total 10 (8.8%) 13 (11.4%) 91 (79.8%) 114 (100%)
Table XVI : Chi-square tests based on outcomes (Gender)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 2.798a 2 .247
Likelihood Ratio 4.349 2 .114
N of Valid Cases 114
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 1.49
Table XVII : ANOVA based on outcomes (Age)
Sum of Squares df Mean Square F Sig.
Between Groups 455.573 2 227.787 1.202 .304
Within Groups 21026.708 111 189.430
Total 21482.281 113
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Table XVIII : Cardiac and Non-cardiac patient outcomes
Euthyroid Hyperthyroid Hypothyroid Total
Cardiac No 7 (7.9%) 8 (9.0%) 74 (83.1%) 89 (100%)
Yes 3 (12.0%) 5 (20.0%) 17 (68.0%) 25 (100%)
Total 10 (8.8%) 13 (11.4%) 91 (79.8%) 114 (100%)
Table XIX : Chi-square tests based on outcomes (Cardiac)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 3.017a 2 .221
Likelihood Ratio 2.746 2 .253
Linear-by-Linear Association 1.887 1 .170
N of Valid Cases 114
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 2.19
Table XX : Carbimazole effect on Outcome
Euthyroid Hyperthyroid Hypothyroid Total
Carbimazole No 3 (11.5%) 5 (19.2%) 18 (69.2%) 26 (100%)
Yes 7 (8.0%) 8 (9.1%) 73 (83%) 88 (100%)
Total 10 (8.8%) 13 (11.4%) 91 (79.8%) 114 (100%)
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Table XXI : Chi-square tests based on outcomes Carbimazole
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 2.577a 2 .276
Likelihood Ratio 2.364 2 .307
Linear-by-Linear Association 1.564 1 .211
N of Valid Cases 114
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 2.28
Table XXII : ANOVA based on outcomes (TFTs)
Sum of Squares df Mean Square F Sig.
TSH Between Groups 23.136 2 11.568 .501 .607
Within Groups 2564.576 111 23.104
Total 2587.712 113
FT4 Between Groups 693.508 2 346.754 .379 .686
Within Groups 101592.902 111 915.251
Total 102286.410 113
FT3 Between Groups 436.245 2 218.123 1.242 .293
Within Groups 19497.172 111 175.650
Total 19933.417 113
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Table XXIII : Initial dose of RAI and Outcome
Euthyroid Hyperthyroid Hypothyroid Total
Dose
Low 0 3 (12%) 22 (88%) 25 (100%)
Intermediate 7 (14.3%) 4 (8.2%) 38 (77.6%) 49 (100%)
High 3 (7.5%) 6 (15%) 31 (77.5%) 40 (100%)
Total 10 (8.8%) 13 (11.4%) 91 (79.8%) 114 (100%)
Table XXIV : Chi-square tests based on outcomes (Dose)
Value df Asym. Sig. (2-sided)
Pearson Chi-Square 5.146a 4 .273
Likelihood Ratio 7.071 4 .132
Linear-by-Linear Association .895 1 .344
N of Valid Cases 114
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 2.19
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Table XXV : Intergroup analysis Bonferroni tests based on outcomes (Total Dose)





Euthyroid Hyperthyroid -6.946 1.936 .001 -11.65 -2.24
Hypothyroid 2.719 1.533 .237 -1.01 6.45
Hyperthyroid Euthyroid 6.946 1.936 .001 2.24 11.65
Hypothyroid 9.665 1.365 .000 6.35 12.98
Hypothyroid Euthyroid -2.719 1.533 .237 -6.45 1.01
Hyperthyroid -9.665 1.365 .000 -12.98 -6.35
